{"id":"W2892012428","doi":"10.1200/jco.2016.34.15_suppl.3546","title":"IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Hazard ratio; Gastroenterology; Colorectal cancer; Clinical endpoint; Progression-free survival; Randomized controlled trial; KRAS; Chemotherapy; Surgery; Oncology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00199459,0.0002026477,0.001863332,0.0001277347,0.00002542939,0.000007665914,0.0002367483,0.0002015846,0.0001062208],"category_scores_gemma":[0.002340832,0.00008897912,0.0003201955,0.0001483824,0.0005216763,0.00001948514,0.00006101495,0.0002913892,0.000002440437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001370971,"about_ca_system_score_gemma":0.003170893,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002249331,"about_ca_topic_score_gemma":0.003409134,"domain_scores_codex":[0.996204,0.001015707,0.00170317,0.0002868196,0.0004670009,0.0003233608],"domain_scores_gemma":[0.996392,0.0008715455,0.001776524,0.0001926992,0.0004911587,0.0002760711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9011503,0.004246862,0.01998707,0.00001305232,0.001396474,0.000148289,0.00003491505,0.000004389964,0.0007861336,0.000004340048,0.000208695,0.07201949],"study_design_scores_gemma":[0.895893,0.09471848,0.002284214,0.0001237544,0.0003656642,0.00003648068,0.0000217598,0.000006035137,0.003691128,0.00004435461,0.002681735,0.0001334202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977065,0.0002144223,0.000238628,0.0003262405,0.0002569064,0.0009792564,0.00004663238,0.000002024594,0.0002293831],"genre_scores_gemma":[0.9972851,0.001063186,0.0009780827,0.0001205293,0.0002591342,0.00009666575,0.000007297495,0.00002333744,0.0001666875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09047162,"threshold_uncertainty_score":0.5625027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.073541251622984,"score_gpt":0.4775817518546719,"score_spread":0.4040405002316879,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}